Skip to content

Multi-platform Metabolomics Technology and Presicion Prediction of Type 2 Diabetes

Multi-platform Metabolomics Technology and Presicion Prediction of Type 2 Diabetes

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036927
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

newly diagnosed diabetic patients :Nil
control group:Nil

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The study uses a nested case-control method to select 200 newly diagnosed diabetic patients identified during follow-up into the case group. The control group will be matched at a ratio of 1:1. The matching factors include age, gender, ethnicity and fasting blood glucose.

Exclusion criteria

Exclusion criteria: 1) history of cancer; 2) history of cardiovascular disease; 3) history of autoimmune diseases such as LADA; 4) acute diabetic complications, acidosis, etc.; 5) moderate to severe liver and kidney dysfunction, namely ALT /AST> is 2.5 times the upper limit of the normal range or Ccr<25ml/min; 6) Any other diseases or major systemic diseases that will affect trial participation or result evaluation.

Design outcomes

Primary

MeasureTime frame
Type 2 diabetes;

Countries

China

Contacts

Public ContactYufang Bi

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

byf10784@rjh.com.cn+86 13917189212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026